Lorlatinib vs crizotinib in treatment-naïve patients with advanced ALK + non-small cell lung cancer: 5-year progression-free survival and safety from the CROWN study.

Authors :: Solomon, Benjamin J.
Liu, Geoffrey
Felip, Enriqueta
Mok, Tony S. K.
Soo, Ross Andrew
Mazieres, Julien
Shaw, Alice Tsang
de Marinis, Filippo
Goto, Yasushi
Wu, Yi-Long
Kim, Dong-Wan
Martini, Jean-Francois
Messina, Rossella
Paolini, Jolanda
Polli, Anna
Thomaidou, Despina
Toffalorio, Francesca
Bauer, Todd Michael
Source :: Journal of Clinical Oncology; 2024 Supplement 17, Vol. 42, pLBA8503-LBA8503, 83p
Publication Year :: 2024

Full Text Access

Tools